Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Matsumoto, Nagano Prefecture, Japan, founded in 1946. The company specializes in the development of pharmaceuticals for urology, neurology, and immunology, with a growing focus on central nervous system disorders including [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative conditions [1].
...
Overview
Mermaid diagram (expand to render)
Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Matsumoto, Nagano Prefecture, Japan, founded in 1946. The company specializes in the development of pharmaceuticals for urology, neurology, and immunology, with a growing focus on central nervous system disorders including [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative conditions [1].
The company has established partnerships with international biotech firms to expand its neuroscience pipeline and has invested in novel drug delivery technologies for CNS disorders [2].
α-Synuclein aggregation: Developing small molecule inhibitors to prevent toxic protein aggregation in [Parkinson's disease](/diseases/parkinsons-disease)
Dopamine modulation: Novel dopamine stabilizers to normalize dopaminergic signaling
Neuroprotection: Compounds aimed at protecting dopaminergic [neurons](/cell-types/neurons) from degeneration
Recent Developments
2024-2025
Expanded neuroscience R&D through academic partnerships with Japanese universities
Initiated discovery programs for Parkinson's disease drug candidates
Strengthened intellectual property portfolio for α-synuclein targeting compounds
2023
Established collaboration with US biotech for CNS drug development
Reported positive results for naldemedine in additional markets
Partnerships
Kissei has established partnerships with:
International pharmaceutical companies for Japanese market authorization
Academic research institutions for basic neuroscience research
US biotech companies for drug development collaboration
Dr. Masahiko Saito (Director, Neuroscience Research)
Market Position
Kissei Pharmaceutical maintains a strong position in the Japanese pharmaceutical market, particularly in the urology and neurology segments. The company's focus on niche therapeutic areas has allowed it to establish leadership positions without competing directly with major pharmaceutical companies [1].
The company's domestic market presence is complemented by international partnerships that provide access to global markets. Kissei's strategy emphasizes partnerships over direct commercialization in international markets [2].
Manufacturing Capabilities
Kissei operates manufacturing facilities in Matsumoto, Nagano Prefecture, which produce both active pharmaceutical ingredients and finished dosage forms. The facilities maintain GMP certification and have been inspected by regulatory authorities in Japan, the United States, and Europe [1].
Corporate Social Responsibility
Kissei is committed to corporate social responsibility initiatives in healthcare access, environmental sustainability, and community engagement. The company supports healthcare programs in developing countries and participates in industry-wide initiatives to improve pharmaceutical accessibility [3].
Future Outlook
Looking forward, Kissei Pharmaceutical aims to become a leading neuroscience company in Japan. The company's strategy includes:
Pipeline expansion: Adding 2-3 new neuroscience programs annually
Partnership development: Increasing academic and industry collaborations
Geographic expansion: Entering new Asian markets
Talent acquisition: Recruiting top neuroscience researchers